Xgeva Solution For Injection 70Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

XGEVA: Solution for injection (70mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

DENOSUMAB (den oh sue mab) slows bone breakdown. Prolia is used to treat osteoporosis in women after menopause and in men. Xgeva is used to prevent bone fractures and other bone problems caused by cancer bone metastases. Xgeva is also used to treat giant cell tumor of the bone.

Similar Brand Name Drugs : Prolia: Solution for injection (60mg)
In-Depth Information

XGEVA 120mg/1.7ml Solution for Injection

NDC: 555130730
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Giant Cell Tumor Of Bone, Osteoporosis Prophylaxis, Osteoporosis, Bone Metastases, Hypercalcemia

Storage Information
Protect from light
Product must be used within 14 days after removal from refrigeration to room temperature (77 degrees F)
Discard product if it contains particulate matter, is cloudy, or discolored
Store in original container
Do not expose product to temperatures above 77 degrees F
Protect from extreme heat
Store unopened containers in refrigerator (36 to 46 degrees F)
Do not freeze
Protect from direct sunlight
Discard within 14 days after first use
XGEVA 120mg/1.7ml Solution for Injection

Reported Side Effects for XGEVA 120mg/1.7ml Solution for Injection

Low Phosphate Level Incidence:
<15.4%*
Severity: SEVERE
Onset: DELAYED
Low Magnesium Levels Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Low Calcium Levels Incidence:
<3.1%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
Fluid Retention Incidence:
<24.0%*
Severity: MODERATE
Onset: DELAYED
Dead Bone Incidence:
0.7-7.1%*
Severity: SEVERE
Onset: DELAYED
Heartburn Incidence:
2.1%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
2.2%*
Severity: MILD
Onset: RAPID
Gas Incidence:
2.2%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
2.3-45.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
2.5%*
Severity: MILD
Onset: EARLY
Muscle Pain Incidence:
>3.0%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
3.3%*
Severity: MILD
Onset: EARLY
Bone Pain Incidence:
4.0-19.0%*
Severity: MODERATE
Onset: DELAYED
Anemia Incidence:
4.0-21.0%*
Severity: MODERATE
Onset: DELAYED
Muscle And/Or Bone Pain Incidence:
>8.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cells Incidence:
>9.0%*
Severity: MODERATE
Onset: DELAYED
Back Pain Incidence:
10.0-34.7%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
10.0-24.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
>10.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
10.0-31.0%*
Severity: MILD
Onset: EARLY
Chills Incidence:
>11.0%*
Severity: MILD
Onset: RAPID
Fever Incidence:
>11.0%*
Severity: MILD
Onset: EARLY
Cough Incidence:
>15.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
20.0%*
Severity: MILD
Onset: EARLY
Shortness Of Breath Incidence:
21.0-27.0%*
Severity: MODERATE
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with XGEVA

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5